VentriPoint Diagnostics (TSXV:VPT) Cash-to-Debt : 3.14 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is VentriPoint Diagnostics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. VentriPoint Diagnostics's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.14.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, VentriPoint Diagnostics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for VentriPoint Diagnostics's Cash-to-Debt or its related term are showing as below:

TSXV:VPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 3.22 Max: No Debt
Current: 3.14

During the past 13 years, VentriPoint Diagnostics's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 3.22.

TSXV:VPT's Cash-to-Debt is ranked better than
57.87% of 864 companies
in the Medical Devices & Instruments industry
Industry Median: 1.845 vs TSXV:VPT: 3.14

VentriPoint Diagnostics Cash-to-Debt Historical Data

The historical data trend for VentriPoint Diagnostics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

VentriPoint Diagnostics Cash-to-Debt Chart

VentriPoint Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.01

0.38

57.93

11.30

3.14

VentriPoint Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															11.30	9.29	7.49	5.38	3.14

Competitive Comparison of VentriPoint Diagnostics's Cash-to-Debt

For the Medical Devices subindustry, VentriPoint Diagnostics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VentriPoint Diagnostics's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where VentriPoint Diagnostics's Cash-to-Debt falls into.

VentriPoint Diagnostics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

VentriPoint Diagnostics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.294	/	(0.115	+	0.297)
	=	3.14

VentriPoint Diagnostics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.294	/	(0.115	+	0.297)
	=	3.14

VentriPoint Diagnostics (TSXV:VPT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

VentriPoint Diagnostics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of VentriPoint Diagnostics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

VentriPoint Diagnostics (TSXV:VPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » VentriPoint Diagnostics Ltd (TSXV:VPT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

VPTDF:USA 5V7:Germany

Address

18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4

Website

https://www.ventripoint.com

VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It develops applications for heart diseases and imaging modalities which includes congenital heart disease, left or right heart failure, and normal hearts. It sells its products in Canada and internationally.

Executives

Robert Hodgkinson

Director

VentriPoint Diagnostics (TSXV:VPT) Headlines

No Headlines